Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Escitalopram and Biomarkers in MDD
NCT01997580Phase 4Unknown
- Sponsor
- Seoul National University Bundang Hospital
- Start
- Jul 2013
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of escitalopram in major depressive disorder (MDD) (2 arms), sponsored by Seoul National University Bundang Hospital. Primary endpoint: Change in baseline frequency of maximum of cross-spectrum at 42 days. Status: unknown.
02
Drugs
escitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01997580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01997580.